BioCentury | Feb 15, 2016
Clinical News

AKB-9778: Additional Phase IIa data

...July 20, 2015). Aerpio Therapeutics Inc. , Cincinnati, Ohio Product: AKB-9778 Business: Ophthalmic Molecular target: Protein tyrosine phosphatase receptor type D (PTPRD) (HPTP) beta...
BioCentury | Jul 20, 2015
Clinical News

AKB-9778: Phase IIa data

...longer treatment duration. Aerpio Therapeutics Inc. , Cincinnati, Ohio Product: AKB-9778 Business: Ophthalmic Molecular target: Protein tyrosine phosphatase receptor type D (PTPRD) (HPTP) beta...
BioCentury | Mar 16, 2015
Clinical News

AKB-9778: Additional Phase Ib/IIa data

...Nov. 11, 2013). Aerpio Therapeutics Inc. , Cincinnati, Ohio Product: AKB-9778 Business: Ophthalmic Molecular target: Protein tyrosine phosphatase receptor type D (PTPRD) (HPTP) beta...
BioCentury | Dec 15, 2014
Clinical News

AKB-9778: Completed Phase II enrollment

...vs. Lucentis alone. Aerpio Therapeutics Inc. , Cincinnati, Ohio Product: AKB-9778 Business: Ophthalmic Molecular target: Protein tyrosine phosphatase receptor type D (PTPRD) (HPTP) beta...
BioCentury | Feb 17, 2014
Clinical News

AKB-9778: Phase II started

...markets it elsewhere. Aerpio Therapeutics Inc. , Cincinnati, Ohio Product: AKB-9778 Business: Ophthalmic Molecular target: Protein tyrosine phosphatase receptor type D (PTPRD) (HPTP) beta...
BioCentury | Nov 11, 2013
Clinical News

AKB-9778: Phase Ib/IIa data

...Jan. 16, 2012). Aerpio Therapeutics Inc. , Cincinnati, Ohio Product: AKB-9778 Business: Ophthalmic Molecular target: Protein tyrosine phosphatase receptor type D (PTPRD) (HPTP) beta...
BioCentury | Sep 24, 2012
Clinical News

AKB-9778: Phase Ib/IIa started

...BioCentury, Jan. 16). Aerpio Therapeutics Inc. , Cincinnati, Ohio Product: AKB-9778 Business: Ophthalmic Molecular target: Protein tyrosine phosphatase receptor type D (PTPRD) (HPTP) beta...
BioCentury | Mar 26, 2012
Clinical News

AKB-9778: Phase I data

...BioCentury, Jan. 16). Aerpio Therapeutics Inc. , Cincinnati, Ohio Product: AKB-9778 Business: Ophthalmic Molecular target: Protein tyrosine phosphatase receptor type D (PTPRD) (HPTP) beta...
BioCentury | Dec 5, 2011
Clinical News

AKB-9778: Phase I started

Akebia began a U.S. Phase I trial to evaluate single ascending-doses of AKB-9778 in up to 48 healthy volunteers. Akebia Therapeutics Inc. , Cincinnati, Ohio Product: AKB-9778 Business: Ophthalmic Molecular target: Angiopoietin 2 (ANG2) (ANGPT2) Description:...
Items per page:
1 - 9 of 9